Clinical antiviral effects of telbivudine in patients with chronic hepatitis B / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 259-262, 2010.
Artículo
en Chino
| WPRIM
| ID: wpr-247541
ABSTRACT
<p><b>OBJECTIVE</b>To analyze antiviral effects of telbivudine in patients with chronic hepatitis B.</p><p><b>METHOD</b>72 chronic hepatitis B patients without prior history of antiviral therapy were treated with telbivudine 600mg once daily.</p><p><b>RESULTS</b>At week 4, 37.5% of the patients achieved undetectable HBV DNA, and 33.3% achieved ALT normalization. At week 108, 87.5% of the patients achieved undetectable HBV DNA, and 91.7% achieved ALT normalization. HBeAg seroconversion occurred in 23.9% of the 46 HBeAg positive patients. The rates of undetectable HBV DNA and HBeAg seroconversion at week 108 in the patients with HBV DNA < 3 log(10) copies/ml at week 12 were significant higher than those in patients with HBV DNA >or= 3 log(10) copies/ml. The rate of undetectable HBV DNA at week 108 in the patients with HBV DNA < 3 log(10) copies/ml at week 24 was significantly higher than that in patients with HBV DNA >or= 3 log(10) copies/ml, and the rate of antiviral resistance rate at week 108 in the patients with HBV DNA < 3 log(10) copies/ml at week 24 was significantly lower than that in patients with HBV DNA >or= 3 log(10) copies/ml. Antiviral therapy could significantly improve Child-Pugh score in patients with liver cirrhosis.</p><p><b>CONCLUSION</b>Telbivudine treatment results in suppression of HBV and high HBeAg seroconversion, and improvement of Child-Pugh score in the patients with liver cirrhosis.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Fisiología
/
Pirimidinonas
/
Timidina
/
Virología
/
Replicación Viral
/
Sangre
/
ADN Viral
/
Virus de la Hepatitis B
/
Resultado del Tratamiento
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Chinese Journal of Hepatology
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS